Jupiter Topco’s ARS Pharmaceuticals SPRY Stock Holding History

Jupiter Topco’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	+21,600	New	+$186K	﹤0.01%	2427

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jupiter Topco's SPRY Position: Q2 2026 in Review

Jupiter Topco opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 21,600 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #2427 among its holdings.

192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Jupiter Topco held 21,600 shares of ARS Pharmaceuticals worth $173K as of Q2 2026.
ARS Pharmaceuticals was a new Jupiter Topco position in Q2 2026.
ARS Pharmaceuticals made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2427 holding.
192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.